Choose ALUNBRIG® (brigatinib), Which Offers Efficacy in Previously Treated Patients

Brigatinib (ALUNBRIG) is an NCCN Category 2A recommended treatment option for patients post-crizotinib.1


The efficacy of ALUNBRIG was studied in a global, two-arm, open-label, multicenter study of adult patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who had progressed on crizotinib.2,3

In a randomized 1:1 study of 222 adult patients with locally advanced or metastatic ALK+ NSCLC that progressed on crizotinib, the median duration of follow up was 8 months.

Major efficacy outcome measure was confirmed overall response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) as evaluated by an Independent Review Committee (IRC).2

Additional efficacy outcome measures included investigator-assessed ORR, duration of response (DOR), intracranial ORR, and intracranial DOR.


ALUNBRIG was studied in patients with locally advanced or metastatic ALK+ NSCLC.

Graph of patients' demographic at trial entry.

ALUNBRIG demonstrated clinically meaningful overall response rates (ORR) following crizotinib2

Results from 8-month median follow-up2,a

In a 2-year median follow-upd—ALUNBRIG achieved meaningful PFS and OS after treatment with crizotinib3

Study Limitations: ALTA was not a controlled trial and was not prospectively designed for statistical comparisons between dosing arms.

In an 8-month median follow-up—ALUNBRIG had clinically meaningful intracranial responses post-crizotinib2

Results from 8-month median follow-up2,a

Duration of intracranial response was measured from date of first intracranial response until intracranial disease progression (new lesions, intracranial target lesion diameter growth ≥20% from nadir, or unequivocal progression of nontarget lesions) or death.

In a 2-year median follow-upd—ALUNBRIG achieved meaningful intracranial PFS post-crizotinib3

aThe median duration of follow-up was 8 months (range: 0.1-20.2).2
bThe recommended dosing regimen is 90 mg orally once daily for the first 7 days; then increase the dose to 180 mg orally once daily.2
c≥10 mm in longest diameter (at baseline).
dAdditional outcomes calculated as of September 29, 2017, 2 years after last enrollment (median follow-up of 19.6 months [range: 0.1-35.2] in the 90-mg arm and 24.3 months [range: 0.1-39.2] in the 90→180-mg arm).3

ALK, anaplastic lymphoma kinase; ALK+, ALK-positive; NCCN, National Comprehensive Cancer Network® (NCCN®); ECOG, Eastern Cooperative Oncology Group; PR, partial response.